2月14日盘中,微创机器人-B(股份代号:02252)股价出现大涨,最高升幅达到7.11%,引发市场广泛关注。
消息面上,微创机器人发布公告,公司自主研发的图迈单臂单孔腔镜手术机器人(图迈单臂)获得国家药品监督管理局的注册批准。这意味着图迈单臂整体性能、创新水平及临床有效性、安全性都获得了国家权威监管部门的认证。
分析人士指出,此次注册批准是利好消息,代表着微创机器人"五分之四"机器人版图已全部就绪,未来几年是公司重要的扭亏拐点期。同时,海内外市场需求旺盛,公司订单量连续两年实现翻倍以上增长。因此,获批将有助于公司持续拓展产品管线,提高公司在手术机器人领域的竞争力,市场对其长期增长前景更加看好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.